Parmax Pharma Ltd.
Snapshot View

View in App

Prices View details

56.20 +0.15 ▲0.3%

30 July 2021, 04:00:00 P.M.
Volume: 55

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.parmaxpharma.com
Financial Indicators
Market Cap 21.03 Cr.
Earnings per share (EPS) 2.02 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 27.89 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 9.42 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.97 Calculated using Price: 56.20
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.37 Cr. 3,741,300 Shares
FaceValue 10
Company Profile

Parmax Pharma was incorporated on November 02, 1994. The certificate of commencement of business was received by the company on March 10, 1995.The IPO of the company was January 30, 1996 with 5100800 shares of Rs10/-each. The promoters were earlier in manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The company then discontinued its business activities for few years due to various reasons. The company also plans to extend its activity in formulation of Tablets, Capsules, Ointments, & Injectable.

Objective

The objective of the company is to carry on business as manufacturers, producers, refiners, mixers, processors, repackers, distillers, formulators, convertors, extractors, buyers, sellers, wholesalers, retailers, distributors, suppliers, importers, extractors, or otherwise to deal in all kinds of drug and drugs used in pharmaceutical, medicinal biological immunological, contraceptive and therapeutim preparations, substance materials and articles of all classes and description whether simple compound or otherwise, and also drugs used in disinfectants, antiseptic and of cordials antibiotics tinctures lozenges syrups, capsules, tablets, tablets inject able , liquid lotions ointments, restoratives, vitamins, nonmones , ayurvedic, medicines, proprietory medicines, pharmaceutical chemicals, chemical compounds having chemical properties.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.27%
1 Week
+3.88%
1 Month
-10.37%
3 Month
-1.49%
6 Month
+87.65%
1 Year
+89.86%
2 Year
+209.64%
5 Year

Ratios View Details

9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -0.05 -0.96 1.16 0.70 -0.12 -0.28 0.02 3.71 18.19
Return on Capital Employed (%) -0.04 -0.74 1.01 0.88 0.28 0.18 0.81 1.96 10.19
Return on Assets (%) -0.03 -0.61 0.73 0.45 -0.08 -0.12 0.00 0.43 2.11

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 4 4 4 4 5 5 5 5 5
Non Curr. Liab. 1 1 1 1 0 1 2 5 5
Curr. Liab. 0 0 0 0 0 2 10 10 11
Minority Int.
Equity & Liab. 5 5 5 5 5 8 17 20 21
Non Curr. Assets 3 3 3 3 3 3 6 9 10
Curr. Assets 1 1 2 2 2 4 9 9 9
Misc. Exp. not W/O 1 1 1 1 1 1 2 2 2
Total Assets 5 5 5 5 5 8 17 20 21

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 12 12 21
Other Income 0 0 0 0 0 0 0
Total Income 0 0 0 0 12 12 21
Total Expenditure 0 0 0 0 0 -11 -11 -19
PBIDT 0 0 0 0 0 1 1 2
Interest 0 0 0
Depreciation -1 -1 -1
Taxation 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 -1 4 1 3
Cash Fr. Inv. 0 -4 -3 -2
Cash Fr. Finan. 0 0 0 1 1 3 0
Net Change 0 0 0 1 1 0
Cash & Cash Eqvt 0 0 0 0 0 0 1 2 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80 30.80
Public 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20 69.20
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 19 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30th June 2021
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- YASH VORA
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 30 Jul 2021
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
MACD Crossing Signal Line From Below MACD Crossing Signal Line From Below
ATR Decreasing for 3 Days ATR Decreasing for 3 Days
Thu, 29 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%